6,058 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by BridgePort Financial Solutions LLC

BridgePort Financial Solutions LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 6,058 shares of the company's stock, valued at approximately $540,000.

Several other hedge funds have also recently bought and sold shares of the company. Center for Financial Planning Inc. lifted its position in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its position in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period. Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $29,000. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $39,000. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on NVO shares. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Stock Up 2.6%

NYSE NVO traded up $1.83 on Friday, reaching $71.29. The company had a trading volume of 7,181,287 shares, compared to its average volume of 6,756,461. The stock has a market capitalization of $319.92 billion, a P/E ratio of 21.67, a P/E/G ratio of 0.90 and a beta of 0.65. The company's fifty day moving average is $65.63 and its 200 day moving average is $82.01. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The business had revenue of $11.87 billion during the quarter. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.